R. Deshpande, Aishwarya P. Joshi, N. Tandel, R. Tyagi
{"title":"诊断","authors":"R. Deshpande, Aishwarya P. Joshi, N. Tandel, R. Tyagi","doi":"10.2174/9781681088082121010009","DOIUrl":null,"url":null,"abstract":"Summary IKAROS, a zinc finger transcription factor protein encoded by the IKZF1 gene is crucial for hematopoiesis in humans. Loss of function mutations in IKZF1 have been implicated in adult and pediatric B cell Acute Lymphoblastic Leukemia (B-ALL). Our aim is to evaluate the incidence of IKAROS protein expression and IKZF1 mRNA transcripts in B-ALL patients. IKAROS protein expression was evaluated in total 34 patients diagnosed as de-novo B-ALL using flow cytometry and IKZF1 mRNA Transcripts were detected using reverse transcriptase - polymerase chain reaction (RT-PCR) method in 13 patients. The expression levels of the IKAROS protein and IKZF1 isoforms were analysed and correlated with clinical and hematological parameters. B-ALL patients with presence of only IK-6 isoform were associated with high WBC count, blast count (>85%) as well as progenitor cell markers CD34 and Tdt positivity. Also there was a significant correlation of low hemoglobin and CD19 positivity with IKAROS protein over expression. In one of the patient we found only 09% of IKAROS protein, having two dominant negative isoforms IK-4 and IK-6 with absence of normal isoforms, which might suggest disease aggressiveness. However, IKAROS protein evaluation by flow cytometry method should be correlated with IKAROS isoforms in more number of B-ALL patients so that the clinical relevance of IKAROS protein could be established. Correlation with conventional prognostic markers suggests that the patients showing the presence of IK-6 isoform can be considered as high risk patients.","PeriodicalId":121110,"journal":{"name":"COVID-19: Diagnosis and Management-Part I","volume":"31 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diagnosis\",\"authors\":\"R. Deshpande, Aishwarya P. Joshi, N. Tandel, R. Tyagi\",\"doi\":\"10.2174/9781681088082121010009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary IKAROS, a zinc finger transcription factor protein encoded by the IKZF1 gene is crucial for hematopoiesis in humans. Loss of function mutations in IKZF1 have been implicated in adult and pediatric B cell Acute Lymphoblastic Leukemia (B-ALL). Our aim is to evaluate the incidence of IKAROS protein expression and IKZF1 mRNA transcripts in B-ALL patients. IKAROS protein expression was evaluated in total 34 patients diagnosed as de-novo B-ALL using flow cytometry and IKZF1 mRNA Transcripts were detected using reverse transcriptase - polymerase chain reaction (RT-PCR) method in 13 patients. The expression levels of the IKAROS protein and IKZF1 isoforms were analysed and correlated with clinical and hematological parameters. B-ALL patients with presence of only IK-6 isoform were associated with high WBC count, blast count (>85%) as well as progenitor cell markers CD34 and Tdt positivity. Also there was a significant correlation of low hemoglobin and CD19 positivity with IKAROS protein over expression. In one of the patient we found only 09% of IKAROS protein, having two dominant negative isoforms IK-4 and IK-6 with absence of normal isoforms, which might suggest disease aggressiveness. However, IKAROS protein evaluation by flow cytometry method should be correlated with IKAROS isoforms in more number of B-ALL patients so that the clinical relevance of IKAROS protein could be established. Correlation with conventional prognostic markers suggests that the patients showing the presence of IK-6 isoform can be considered as high risk patients.\",\"PeriodicalId\":121110,\"journal\":{\"name\":\"COVID-19: Diagnosis and Management-Part I\",\"volume\":\"31 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"COVID-19: Diagnosis and Management-Part I\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/9781681088082121010009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"COVID-19: Diagnosis and Management-Part I","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/9781681088082121010009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Summary IKAROS, a zinc finger transcription factor protein encoded by the IKZF1 gene is crucial for hematopoiesis in humans. Loss of function mutations in IKZF1 have been implicated in adult and pediatric B cell Acute Lymphoblastic Leukemia (B-ALL). Our aim is to evaluate the incidence of IKAROS protein expression and IKZF1 mRNA transcripts in B-ALL patients. IKAROS protein expression was evaluated in total 34 patients diagnosed as de-novo B-ALL using flow cytometry and IKZF1 mRNA Transcripts were detected using reverse transcriptase - polymerase chain reaction (RT-PCR) method in 13 patients. The expression levels of the IKAROS protein and IKZF1 isoforms were analysed and correlated with clinical and hematological parameters. B-ALL patients with presence of only IK-6 isoform were associated with high WBC count, blast count (>85%) as well as progenitor cell markers CD34 and Tdt positivity. Also there was a significant correlation of low hemoglobin and CD19 positivity with IKAROS protein over expression. In one of the patient we found only 09% of IKAROS protein, having two dominant negative isoforms IK-4 and IK-6 with absence of normal isoforms, which might suggest disease aggressiveness. However, IKAROS protein evaluation by flow cytometry method should be correlated with IKAROS isoforms in more number of B-ALL patients so that the clinical relevance of IKAROS protein could be established. Correlation with conventional prognostic markers suggests that the patients showing the presence of IK-6 isoform can be considered as high risk patients.